SLC5A2 and chronic kidney disease: Establishing definitively whether or not albuminuria is a prerequisite for renal benefits of SGLT-2 inhibitors remains an important question, as the vast majority of people with decreased eGFR do not have albuminuria [43], and CREDENCE and DAPA-CKD provide evidence of efficacy among people with albuminuria [18, 23, 25].